pmc.ncbi.nlm.nih.gov

Multiple Ca2+ Binding Sites in the Extracellular Domain of Ca2+-Sensing Receptor Corresponding to Cooperative Ca2+ Response

. Author manuscript; available in PMC: 2010 Jan 20.

Published in final edited form as: Biochemistry. 2009 Jan 20;48(2):388–398. doi: 10.1021/bi8014604

Abstract

A small change in the extracellular Ca2+ concentration ([Ca2+]o) integrates cell signaling responses in multiple cellular and tissue networks and functions via activation of Ca2+-sensing receptors (CaSR). Mainly through binding of Ca2+ to the large extracellular domain (ECD) of the dimeric CaSR, intracellular Ca2+ responses are highly cooperative with an apparent Hill coefficient ranging from 2 to 4. We have previously reported the identification of two continuous putative Ca2+-binding sites by grafting CaSR-derived, Ca2+-binding peptides to a scaffold protein, CD2, that does not bind Ca2+. In this paper, we predict more potential non-continuous Ca2+-binding sites in the ECD. We dissect the intact CaSR into three globular subdomains, each of which contains 2 to 3 predicted Ca2+-binding sites. This approach enables us to further understand the mechanisms underlying the binding of multiple metal ions to extended polypeptides derived from within the ECD of the CaSR, which would be anticipated to more closely mimic the structure of the native CaSR ECD. Tb3+-luminescence energy transfer, ANS fluorescence, and NMR studies show biphasic metal-binding components and Ca2+-dependent conformational changes in these subdomains. Removing the predicted Ca2+-binding ligands in site 1 and site 3 abolishes the first binding step and second binding step, respectively. Studies on these subdomains suggest the existence of multiple metal-binding sites and metal-induced conformational changes that might be responsible for switching on/off the CaSR by transition between its open inactive form and closed active form.

Keywords: CaSR, calcium binding protein, cooperativity, conformation, calcium homeostasis


The Ca2+-sensing receptor (CaSR) is a seven transmembrane protein that belongs to family C of the superfamily of G protein-coupled receptors (GPCRs), which also includes metabotropic glutamate receptors (mGluR1-8), heterodimeric-gamma-aminobutyric acid B (GABAB) receptors, taste (T1R) receptors, the promiscuous L-α-amino acid receptor (GPRC6A), and several orphan receptors (1). Most of these receptors are characterized by a large extracellular domain (ECD) at the N-terminus, which binds various endogenous agonists. Many physiological functions regulated by the family C GPCRs are mediated through agonist-mediated allosteric modulation of the respective ECDs; thus understanding the properties of ligand-binding sites is crucial for drug design. The CaSR was first cloned by Brown et al. from bovine parathyroid gland more than a decade ago (2). After removal of the N-terminal, 20-residue signal peptide, the functional form of the CaSR contains an ECD with more than 600 residues and shares 27% sequence identity with the corresponding segment of the mGluRs (3).

The CaSR responds to small changes in [Ca2+]o by modulating multiple signaling pathways, including activation of phospholipases C, A2, and D, and inhibition of cAMP production (4, 5). It is thought that binding of Ca2+ to multiple binding sites within the large extracellular domain (ECD) of the CaSR produces intracellular Ca2+ responses ([Ca2+]i) that are highly cooperative, with an apparent Hill coefficient ranging from 2 to 4 (6). More than 200 mutations and polymorphisms have been identified in the CaSR that either inactivate (e.g., have a reduced response to [Ca2+]o) or activate (have an enhanced response to [Ca2+]o) the receptor and are associated with a number of human diseases, including familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism (NSHPT), and autosomal dominant hypoparathyroidism (ADH) (710), which can change the Ca2+ response of the CaSR with regard to its cooperativity and selectivity.

The ECD regions have been proposed to contain the major Ca2+-binding sites and to respond to extracellular Ca2+ ([Ca2+]o) for both the mGluRs and the CaSR, although various regions in the transmembrane segments have also been shown to bind Ca2+ (6, 11, 12). While X-ray crystallography has been the main tool for studying the structure of metal-binding sites (1315), no bound Ca2+ has been observed in the structures of mGluR1 determined with or without its ligand, glutamate (16). To date, successful crystallization of the CaSR ECD has not been reported despite a decade or more of efforts directed to this end. Progress in understanding the mechanism underlying CaSR-mediated responses to extracellular Ca2+ signals has largely been hampered by lack of knowledge regarding the Ca2+-binding sites in this protein (4). While measurement of high Ca2+o-evoked increases in [Ca2+]i (with a Hill coefficient of 2–4) suggests that the CaSR has multiple Ca2+-binding sites, it is not clear how this extracellular Ca2+-sensing protein manages to cooperatively respond to small changes of Ca2+o within a narrow physiological window (1.1–1.3 mM).

With the program GG (17) and MetalFinder (18, 19), a computational algorithm developed in our laboratory based on geometric description, graph theory and key structural features associated with Ca2+-binding sites in proteins, we have identified at least 5 putative Ca2+-binding sites in the CaSR on the basis of model structures (17). Two continuous putative Ca2+-binding sites (denoted site 3 and site 5 in this work) were reported to exhibit intrinsic Ca2+-binding capability that could be probed upon grafting of the respective peptides containing these sites into a scaffold, non-Ca2+-binding protein, CD2 (19). However, it is not clear whether these putative Ca2+-binding sites are able to bind Ca2+ in an environment more closely resembling that of the native protein. The cooperative Ca2+-binding properties of these predicted Ca2+-binding sites were also not examined. In this paper, we applied a subdomain approach to further understand the mechanisms of multiple metal-binding processes by dissecting the intact CaSR ECD into three globular subdomains, each of which contains 2 to 3 predicted Ca2+-binding sites. Studies on these subdomains suggested the existence of multiple metal-binding processes and metal-induced conformational changes that might be responsible for switching on/off the CaSR by promoting transitions between its opened inactive form and closed active form.

MATERIALS AND METHODS

Computational prediction of Ca2+-binding sites from a model structure

The sequence of the ECD regions (residues 1–540) of the human CaSR and mouse mGluR were aligned by the CLUSTALW program (20), and the structural modeling of the CaSR was performed using SWISS-MODEL (21, 22) and the MODELLER (23) based on the structure of mGluR1 (PDB codes: 1EWT(16) and 1ISR(24)). As described previously, the putative Ca2+-binding sites in the CaSR were predicted using the program MetalFinder (18, 19), and the electrostatic potentials were calculated using the program DelPhi (25, 26).

Protein engineering, expression and purification

Three subdomains were amplified from CaSR-pCDNA 3.1(+) (27) and were further subcloned into the pRSET-A vector between the BamHI and EcoRI restriction sites. Site-directed mutagenesis was carried out as described previously (19). As shown in Fig. 1, subdomain 1 (aa 132–300) contains three predicted Ca2+-binding sites (sites 1–3), subdomain 2 (aa 185 to 324) has two predicted Ca2+-binding sites (sites 2 and 3), and subdomain 3 (aa 340–445) includes two putative Ca2+-binding sites (site 4 and site 5). All the DNA sequences were verified by automated sequencing on an ABI PRISM-377 DNA sequencer (Applied Biosystems).

Figure 1.

Figure 1

The location of predicted Ca2+-binding sites and some disease-associated mutations in the CaSR. (a) Modeled structure of subdomain 1 (S132-A300), which contains three putative Ca2+-binding sites (site 1, 2 and 3). (b) Predicted site 1 is located in the hinge region of the ECD of the CaSR. (c–d) The predicted site 2 and site 3. Ca2+-binding ligand residues are shown in gray whereas the disease-associated residues are shown in green.

The recombinant proteins were expressed as (His)6-tag fusion proteins in Escherichia coli BL21(DE3)pLysS, Rosetta(DE3) or Tuner(DE3)pLacI transformed with the plasmid constructs in LB medium with 100 mg/L of ampicillin and were grown at 37 °C. 100–400 μM of isopropyl-β-D-thiogalactopyranoside (IPTG) were added when the O.D.600 reached 0.6 to induce protein expression for another 3 to 4 hours, and cell pellets were collected by centrifugation and stored at −20 °C. The cell pellets were subsequently resuspended in lysis buffer (1% sarcosine and 1 mM EDTA in PBS, pH 7.4) and subjected to sonication. After centrifugation, the clarified supernatants were subjected to affinity chromatography using the Hitrap Ni2+-chelating column (GE Healthcare). The eluates containing the target proteins were extensively dialyzed against 10 mM Tris-HCl buffer (pH 7.4) to remove the residual imidazole. The concentrations of proteins and their mutants were determined using absorption at 280 nm with extinction coefficients of 36,130 M−1 cm−1 for subdomain 1, 34,850 M−1 cm−1 for subdomain 2, and 27,550 M−1 cm−1 for subdomain 3. All the extinction coefficients were calculated from primary sequences according to the method by Gill and von Hippel (28).

Circular dichroism spectroscopy

The CD spectra of samples were recorded in a Jasco-810 spectropolarimeter at 25 °C. For far UV CD measurements, the protein concentrations ranged from 15 to 20 μM, and spectra were recorded using a 1-mm path length cell. For near UV CD, 100 μM of the protein samples were used with a 1-cm path length cell. All spectra were obtained as the average of at least ten scans with a scan rate of 50 nm/min. The ellipticity was measured from 190 to 260 nm or 250 to 320 nm and then converted to mean residue molar ellipticity after subtracting the spectrum of buffer as the blank.

Fluorescence spectroscopy

Fluorescence emission spectra were recorded on a PTI fluorimeter at 25 °C using a 1-cm path length cell. Intrinsic tryptophan fluorescence spectra were recorded from 300 to 400 nm with the excitation wavelength at 282 nm. The slit widths were set as 2 and 4 nm for excitation and emission, respectively. For Tyr/Trp-sensitized Tb3+ luminescence energy transfer (Tb3+-LRET) experiments, emission spectra were collected from 500 to 600 nm with the excitation at 282 nm. Slit widths for excitation and emission were set at 8 and 12 nm, respectively. Protein samples with concentrations ranging from 2 to 3 μM were prepared in 20 mM PIPES, 120 mM NaCl, 10 mM KCl at pH 6.8 to prevent Tb3+ precipitation. A glass filter with cutoff of 320 nm was used to circumvent secondary Raleigh scattering. Protein samples were titrated with Tb3+ by gradually adding appropriate volumes of Tb3+ stock solutions. Two Tb3+ stocks, 100 μM and 1 mM, were prepared for the titration experiment. Both stocks contained the same concentrations of proteins being studied in the respective experimental protocols to avoid dilution of the protein during addition of the Tb3+. For the first binding process, 5–10 μL aliquots of 100 μM Tb3+ stock were added to a 1 ml solution until the first binding process reached a plateau (10–15 points). 5 μL aliquots of 1 mM Tb3+ stock were subsequently added to achieve saturation of the second binding process (8–12 points). The total stock volume used was around 200–250 μL. 15 min was allowed for equilibration of metal-binding following each addition of Tb3+ prior to the next addition. For each data point, the contribution of the Tb3+ background signal was subtracted using the fluorescence of the respective Tb3+ solutions without protein as a control. The fluorescence intensity was normalized by subtracting the contribution of the baseline slope using logarithmic fitting. All the experiments were repeated at least 3 times. For biphasic binding processes, the first step of Tb3+-binding to the protein was obtained by fitting normalized fluorescence intensity data using the equation:

f=([P]T+[M]T+Kd)−([P]T+[M]T+Kd)2−4[P]T[M]T2[P]T (Eq. 1)

where f is the fractional change, Kd is the dissociation constant for Tb3+, and [P]T and [M]T are the total concentrations of protein and Tb3+, respectively.

The second cooperative metal-binding step is fitted using the equation:

ΔS=ΔS1+ΔS2×[M]nKdn+[M]n (Eq. 2)

where, ΔS1 and ΔS2 are the corresponding signal changes for each process, Kd is the apparent binding affinity, and n is the Hill coefficient for the second binding component, respectively, whereas [M] is the free metal concentration and ΔS is the total signal change in the equation.

For binding to a single site, the binding affinity was fitted by the Hill equation:

where ΔS is the total signal change in the equation, Kd is the apparent binding affinity, n is the Hill coefficient, and [M] is the free metal concentration.

ANS binding measurement

For the ANS (8-anilino-1-naphthalenesulfonic acid) binding assay, protein samples were incubated with 40 μM ANS in 50 mM Tris-HCl, 100 mM KCl (pH 7.4), with either 5 mM EGTA or 5 mM Ca2+ at room temperature for 1 h prior to measurement. The excitation wavelength was set at 370 nm and the emission spectra were acquired from 400 to 600 nm. For the Ca2+ titration, the protein concentration was 3 μM and the Ca2+ concentration was varied from 0 mM to 30 mM in 20 mM Tris-HCl, 50 mM KCl, pH 7.4. The free [Ca2+] in the buffers used in the present study without Chelex-100 treatment has been measured to be <10 μM using BAPTA, a calcium specific chelator (data not shown). In view of this, we have paid careful attention to potential contamination by background Ca2+ in buffers and proteins during our initial pilot titration experiments. All buffers were pretreated with Chelex-100 (Bio-Rad). All the glassware and plasticware used in the preparation of samples were pretreated with 2% HNO3 (optima grade; Fisher Scientific) and then rinsed with Chelexed, double-distilled water. Protein samples were extensively dialyzed against Chelex-100-treated buffers. Under such stringent conditions, the Ca2+ dissociation constant was determined to be at ~0.7 mM for the “high affinity” Ca2+ binding site, a value which is at least >70 fold higher than the free, background [Ca2+] in the buffers even without Chelex-100 treatment. Given this fact, we carried out subsequent titration experiments using buffers that were not pretreated of Chelex-100.

Analysis of the Gibbs free energy of metal binding to subdomains

The Gibbs free energies of metal binding to subdomains (the second transition for subdomain 1 and subdomain 2, as well as subdomain 3) were obtained by fitting the Ca2+ or Tb3+ titration data to the model-independent two-site Adair function as previously described (29, 30):

f=e−ΔG1/RT•[M]+2•e−ΔG2/RT•[M]22•(1+e−ΔG1/RT•[M]+e−ΔG2/RT•[M]2) (Eq. 4)

M stands for metal ions. The sum of the two intrinsic free energies of subdomain (ΔGI + ΔGII) is given by the macroscopic free energy ΔG1, and the total free energy of metal binding (ΔGI• ΔGII • ΔGI–II) to both sites in each subdomain is given by the term ΔG2. The term ΔGI–II accounts for any positive or negative intradomain cooperativity within subdomains. It is not possible to obtain intradomain cooperative energy merely from the fluorescence titration data; however, the lower limit of the cooperative free energy (ΔGc) can be estimated by assuming that both sites in each subdomain have equal intrinsic binding constants (ΔGI = ΔGII), which is defined as:

ΔGc=ΔG2−2ΔG1−RTln4 (Eq. 5)

Fluorescence quenching by acrylamide

Acrylamide quenching was performed to assess the solvent accessibility of Trp residues in subdomains before and after the addition of Ca2+. A 1-mL solution of 5 μM protein in 50 mM Tris, 135 mM NaCl, 10 mM KCl at pH 7.4 was titrated with 10–20 μL aliquots of a 4 M acrylamide stock solution in the same buffer. All quenching experiments were carried out at 22 °C and repeated three times. The samples were excited at 295 nm, and the fluorescence spectra were recorded from 310–450 nm. The integrated fluorescence intensity from 310–450 nm was plotted as a function of the acrylamide concentration and analyzed according to a modified Stern-Volmer equation by taking into account both collisional and static quenching:

F0F=(1+KSV[Q])eV[Q] (Eq. 6)

where F0 and F are the tryptophan fluorescence intensities in the absence and presence of the quencher, respectively. KSV is the collisional quenching constant, V is the static quenching constant, and [Q] is the quencher concentration.

NMR spectroscopy

One-dimensional 1H NMR spectra were recorded at 25 °C on a Varian 500 MHz NMR spectrometer with a spectral width of 6600 Hz. ~300 μM protein samples were used in 20 mM PIPES-150 mM KCl, 10% D2O, pH 6.8. Appropriate amounts of Ca2+ stock solutions were gradually added into the NMR sample tube. The program FELIX98 (MSI) was used to process NMR data with an exponential line broadening window function of 2 Hz and the suppression of water signal with a Gaussian deconvolution function having a width of 20.

Measurement of [Ca2+]i in cell populations by fluorimetry

The [Ca2+]i responses of wild type and mutant CaSRs were assessed as described by Bai et al. (27). In brief, HEK293 cells transfected with the CaSR or its mutant cDNAs were loaded with Fura-2/AM, and the remaining extracellular Fura-2 AM was washed out before the cells were transferred into a fluorescence cuvette. The fluorescent emission at 510 nm was collected with excitation at 340 and 380 nm at varying levels of [Ca2+]o (0.5–20.5 mM). The ratio of the fluorescence intensities is used to derive the level of [Ca2+]i.

RESULTS

Design of subdomains of CaSR

The three dimensional, globular lobes 1 and 2 are formed by discontinuous protein sequences in the ECD. Fig. 1 and Table 1 show the design and model structures of the subdomains based on homology modeling of the different forms of mGluR1 (19). Using our previously developed computational algorithms (17), we have predicted several potential Ca2+-binding pockets in the CaSR (19). These predicted Ca2+-binding sites could be organized into two classes as shown in Fig. 1 and Table 1, two continuous Ca2+-binding sites (sites 3 and 5) and three non-continuous Ca2+-binding sites (sites 1, 2 and 4).

Table 1.

Properties of subdomains and predicted Ca2+-binding sites in each subdomain

Protein Amino acid from CaSR Location Cys No. PI MW (KDa) Predicted Ca2+-binding sites Mutations
Subdomain 1 S132-A300 Lobe 1
Lobe 2
1 4.95 22.9 Site 1 (S147, S170, D190, Y218, E297)
Site 2 (D215, L242, S244, D248, Q253)
Site 3 (E224, E228, E229, E231, E232)
Subdomain 1 mut 1: (D190A/E297I);
Subdomain 1 mut 2: (D215A/D248A)
Subdomain 1 mut 3: (E224I/E228I/E229I/E231I/E232I)
Subdomain 2 R185-A324 Lobe 2 1 4.62 20.3 Site 2 (D215, L242, S244, D248, Q253)
Site 3 (E224, E228, E229, E231, E232)
Subdomain 3 A323-G494 Lobe 1 5 5.05 23.8 Site 4 (E350, E353, E354, N386, S388)
Site 5 (E378, E379, T396, D398, E399)
Subdomain 3 mut 4: (E350I/E353I/E354I);
Subdomain 3 mut 5: (E378I/E379I/D398A/E399I)

The predicted site 1, formed by S147, S170, D190, Y218 and E297, is located within the hinge region of the ECD. Residues of predicted site 2 (D215, L242, S244, D248 and Q253) and site 3 (E224, E228, E229, E231 and E232) are in the first half of the sequence of lobe 2 (aa 215 to 253), whereas the predicted Ca2+-binding sites 4 (E350, E353, E354, N386 and S388) and 5 (E378, E379, T396, D398 and E399) are clustered in the second half of lobe 1 (aa 350 to 400).

Our design of three subdomains of the CaSR is based on four criteria. First, a well-folded globular protein domain is preferred to ensure the formation of an intact Ca2+-binding site. To avoid disruption of structural integrity, the domain boundary is chosen near an unstructured or loop region according to our modeled structure and secondary structure prediction using the programs PHD (31) and PSIPRED (32). Second, a size of <30 KDa is preferred since such a size will allow us to use high resolution NMR to monitor the Ca2+-binding event. Third, the cysteine-rich region within the C-terminal portion of the ECD is not included, since it has been shown to play less important roles in the Ca2+ responsiveness of the CaSR (33). In addition, the cysteine residues, Cys129 and Cys131, which participate in intermolecular disulfide bonds between the CaSR monomers in the biologically active CaSR dimer are excluded in order to limit cooperative effects to those occurring within monomeric subdomains and since they are less likely to be important for the Ca2+ response (e.g. increase of intracellular Ca2+) (34). To obtain the Ca2+-binding affinity of site 1 and to estimate cooperativity, it is important to have a sequence that encompasses site 1 since this site has been shown to be highly important for the proper Ca2+ response (35). According to these criteria, subdomain 1, which spans both lobes 1 and 2, ranges from I132 to A300 and contains putative Ca2+-binding sites 1, 2 and 3; subdomain 2 (aa R185 to A324) contains sites 2 and 3 in lobe 2, and subdomain 3 (aa R323 to L494) contains sites 4 and 5 (Fig. 1, S1a, S1b and Table 1). All these proteins were successfully purified to near homogeneity with over 90% purity (Fig. S1c).

Designed subdomains are folded and bind Ca2+

To ensure that the designed subdomains have proper structures, we carried out conformational analysis using various biophysical methods. First, we examined the secondary and tertiary structures of the subdomains using CD spectroscopy. As shown in Fig. 2a, the far UV CD spectra of subdomains 1, 2 and 3 exhibited negative maxima at 208 and 222 nm, suggesting the existence of substantial helical structure as predicted in the model structure. Next, we examined the intrinsic fluorescence of the subdomains, since each of them contains 2–3 tryptophans. Upon excitation at 282 nm, the Trp fluorescence spectra of subdomains 1, 2 and 3 showed emission maxima at 339, 338 and 334 nm, respectively (Fig. 2b). Moreover, the near UV CD spectra of subdomain 1 showed significant bands in regions corresponding to immobilized aromatic residues (280–300 nm) (Fig. S2a). In subdomain 1, the peaks at 262 and 268 nm arise from the Lb transition of phenylalanine, and the peaks around 288 and 297 nm are attributed to the Lb transition of tryptophan. The positive band in the range of 274–280 nm comes from the La transition of tryptophan. To further estimate the overall solvent accessibility of the tryptophan residues within each subdomain, we performed additional fluorescence quenching studies with acrylamide. As shown in Fig. S2b, the fully exposed free L-tryptophan has a Ksv of 20.9 M−1, whereas the apparent collisional quenching constants Ksv for subdomains 1, 2 and 3 are 3.7, 13.4, and 3.8 M−1, respectively. All these results suggest that the aromatic residues in these three subdomains were at least partially buried, as in other folded proteins.

Figure 2.

Figure 2

CD and fluorescence spectra of subdomains in the absence (dashed line) or presence (solid line) of 5 mM Ca2+. The top, middle and bottom panels for each diagram represent spectra from subdomains 1, 2 and 3, respectively. (a) Far UV CD spectra. (b) Trp fluorescence spectra of subdomains with 5 mM EGTA or 5 mM Ca2+. (c) ANS fluorescence spectra of ANS alone (gray line), and ANS complexed with subdomains with 5 mM EGTA (dashed line) or 5 mM Ca2+ (solid line).

Ca2+-induced conformational changes in subdomains

As shown in Fig. 2a-c (solid lines), the addition of saturating amounts of Ca2+ results in changes in both the Trp fluorescence and CD spectra of the respective subdomains. Notably, more negative signals were acquired above 210 nm for subdomains 1 and 3, suggesting the formation of greater helical contents or the rearrangement of secondary structure induced by Ca2+ in these two proteins. In addition, Ca2+ induced tertiary structural changes in subdomain 1, as suggested by substantially more prominent near UV CD bands around 275 nm and/or 288 nm (Fig. S2a). Ca2+-induced CD signal changes were not significant in subdomain 2. Furthermore, binding of Ca2+ leads to a 3-nm blueshift of the emission maxima and a 15% increase in Trp fluorescence intensity in subdomain 1 and slight intensity changes in both subdomains 2 and 3 (Fig. 2b). Consistent with the changes in fluorescence intensity, the acrylamide quenching studies revealed that the apparent collisional quenching constants for the subdomains were decreased by 10 to 18% (Fig. S2b and Table S1). ANS, a widely used hydrophobic probe, was also used to characterize Ca2+-induced conformational changes. Compared to the Ca2+-depleted proteins, the ANS fluorescence spectra of subdomain 1 in the presence of Ca2+ underwent a 12-nm blueshift and further exhibited a 30% increase in fluorescence intensity (Fig. 2c), suggesting Ca2+-induced exposure of more hydrophobic regions in this protein. Similar intensity increases, though to lesser extents, were detected in subdomains 2 (15%) and 3 (10%), suggesting that Ca2+ induced conformational changes in all three subdomains.

More importantly, such Ca2+-induced blueshifts of emission maxima, as well as the enhancement in the Trp fluorescence (Fig. 3a) or ANS fluorescence intensities (Fig. 3b), were significantly decreased or abolished after mutating predicted Ca2+-binding ligand residues in subdomain 1 (i.e., E297I/D190A in site 1 [subdomain 1 mut 1], D215A/D248A in site 2 [subdomain 1 mut 2] or E224I/E228I/E229I/E231I/E232I in site 3 [subdomain 1 mut 3]). Similar phenomena were observed within subdomain 3 and its mutants (data not shown). Thus, the Ca2+-induced conformational changes primarily arose from its binding to the predicted sites, but were not due to its nonspecific binding to other negatively charged regions.

Figure 3.

Figure 3

Ca2+-induced changes in Trp and ANS fluorescence in subdomains and their charged-ligand mutants (subdomain 1 mut 1: E297I/D190A; subdomain 1 mut 2: D215A/D248A; subdomain 1 mut 3: E224I/E228I/E229I/E231I/E232I). (a) Trp fluorescence spectra of subdomain 1 and its mutants in the presence of 0 (dashed line) and 5 mM Ca2+ (solid line). (b) ANS fluorescence spectra of subdomain 1 and its mutants in the presence of 0 (dashed line) and 5 mM Ca2+ (solid line). The spectrum of ANS alone is shown in gray.

Multiple Metal-Binding Processes

According to the model structure of the ECD of the CaSR, the Trp residues in the subdomains are within 5–10 Å of the closest predicted metal-binding pocket, thus making it possible to use aromatic residue-sensitized Tb3+ luminescence resonance energy transfer (Tb3+-LRET) to monitor the binding process. As a trivalent Ca2+ analog, Tb3+ has been widely used to probe Ca2+-binding sites due to their similarities in ionic radii and coordination chemistry. The advantages of using Tb3+ are threefold: first, its spectroscopic properties for energy transfer between aromatic residues close to the binding pocket and Tb3+ bound in the pocket not only gives quantitative measurements of Kd but also helps to reveal structural information. Second, its 3+ charge, combined with a higher affinity than Ca2+ is a big plus in studying metal-binding properties of proteins with weak Kd’s. Third, background contamination of Tb3+ is smaller than that of Ca2+. A notable biphasic Tb3+ binding process was observed in subdomain 1, which contains three predicted Ca2+-binding sites (sites 1, 2 and 3), as shown in Fig. 4a. The first step could be fitted by a 1:1 binding process with a dissociation constant (Kd) of 0.8 ± 0.3 μM. The second step can be fitted by a cooperative Hill equation with an apparent Kd of 13.2 ± 0.9 μM and a Hill coefficient of 2.3 ± 0.1 (Table 2). For subdomain 3, a cooperative Tb3+-binding curve was obtained with a dissociation constant of 82.0 ± 1.2 μM and a Hill coefficient of 6 (Fig. 4c and Table 2).

Figure 4.

Figure 4

Metal titration of subdomains and their mutants. (a) Tb3+ titration curve of subdomain 1 and its mutants. (b) Ca2+ titration curve of subdomain 1. ANS fluorescence changes were monitored during Ca2+ titration. (c) Tb3+ titration curve of subdomain 3 and its mutants. The buffer for Tb3+ titration consists of 20 mM PIPES, 135 mM NaCl, 10 mM KCl, pH 6.8. The buffer for Ca2+ titration contains 50 mM Tris-HCl, 50 mM KCl, pH 7.4. The titration curve is fitted as described in “Materials and Method”.

Table 2.

Tb3+ dissociation constants for subdomains and their mutants

Protein Transition 1 Transition 2

Kd1 (μM) Kd2 (μM)
Subdomain 1 0.8 ± 0.3 13.2 ± 0.9
Subdomain 1 mut 1 N/A 28.4 ± 0.5 **
Subdomain 1 mut 2 2.2 ± 0.5 21.5 ± 2.7 *
Subdomain 1 mut 3 10.8 ± 4.3 * N/A
Subdomain 2 18.0 ± 5.8 * 27.7 ± 2.6 **
Protein Kd (μM) nhill

Subdomain 3 82.0 ± 1.2 5.8 ± 1.2
Subdomain 3 mut 4 117.1 ± 2.7 ** 5.5 ± 1.9
Subdomain 3 mut 5 132.6 ± 7.9 * 5.1 ± 1.3

We generated a series of charge-ligand mutations at each predicted site in order to knock out metal-binding capability and compare resultant changes in metal-binding behavior. As can be seen in Fig. 4a and Table 2, mutations of predicted site 1 (subdomain 1 mut1) resulted in almost complete loss of the first component of the titration curve with a Kd of 28.4 ± 0.5 μM for the second step, whereas mutations of predicted site 3 (subdomain 1 mut3) led to the elimination of the second phase of the titration curve and showed a Kd of 10.8 ± 4.3 μM for the first step. In the site 2 mutant of subdomain 1 (subdomain 1 mut2), the biphasic binding curve still exists. However, mutations resulted in a >50% decrease in the fluorescence enhancement and significantly weaker binding affinities for both the first (Kd = 2.2 ± 0.5 μM) and second (Kd = 21.5 ± 2.7 μM) steps. The binding curves were right-shifted after the substitution of charged ligand residues in either site of subdomain 3 with Ile (Fig. 4c).

A notably biphasic binding process, similar to the Tb3+-binding curve, was also observed for Ca2+ titration by monitoring ANS fluorescence. The dissociation constants obtained were 0.7 ± 0.1 mM for the first component and 6.4 ± 0.8 mM with a Hill coefficient of 3 for the second component (Fig. 4b). Consistently, two distinct binding components were observed in 1H 1D NMR for subdomain 1. As seen in Fig. 5, resonances in the main chain amide proton region, such as peaks at 7.76 ppm (Fig. 5a) and 7.03 ppm (Fig. 5b), exhibited gradual changes in chemical shift; whereas resonances corresponding to protons from aromatic side chain and methyl groups experienced changes in sudden peak shape and the appearance of more dispersed peaks when the Ca2+ concentration reaches ~2 mM (Fig. S3). An apparent dissociation constant of 1.6 ± 0.1 mM and a Hill coefficient of 2.3 ± 0.2 were obtained by fitting chemical shift changes as a function of total Ca2+ concentration with a nonlinear Hill equation.

Figure 5.

Figure 5

Ca2+ titration of subdomain 1 monitored by 1D 1H NMR. Ca2+-induced, gradual chemical shift changes were observed at resonances in the main chain amide proton region, such as 7.76 ppm (a) and 7.03 ppm (b). The Ca2+ concentrations from bottom to top are: 0, 0.3, 0.7, 1.1, 1.5, 1.9, 2.8, 4.7, and 6.7 mM. (c) Chemical shift change plotted as a function of total Ca2+.

Metal selectivity

In addition to Ca2+, other metal ions, including Mg2+ and Ba2+, are reported to function as agonists for the CaSR as revealed by functional assays (36). By utilizing the Tb3+-LRET assay, we screened an array of monovalent (K+), divalent (Ca2+, Mg2+) and trivalent (La3+) metal ions for their effectiveness in competing for the protein-bound Tb3+. As shown in Fig. 6, for all the subdomains, the addition of 2-fold excess of La3+, 20-fold excess of Ca2+, and 200-fold excess of Mg2+ to the Tb3+-bound proteins is capable of competing for Tb3+ from the binding pockets and leads to a 15–50% decrease in the LRET signal. By comparison, the addition of a 200-fold excess of K+ fails to dislodge Tb3+ from the binding sites.

Figure 6.

Figure 6

Metal competition assay for subdomains on the basis of Tb3+-LRET. Protein samples (2 μM) are preincubated with 50 μM Tb3+. 100 mM KCl, 1 mM CaCl2, 10 mM MgCl2 or 0.1 mM La3+ are subsequently added to individual Tb3+-protein solutions. All the buffers consist of 20 mM PIPES, 135 mM NaCl, 10 mM KCl, pH 6.8.

Metal binding free energies and intradomain cooperativity

The above-mentioned Hill coefficient is widely used to estimate intradomain cooperativity; however, this term only reflects the macroscopic properties of multiple metal-binding processes and is not directly related to the true intradomain cooperative energy changes (37). A more accurate and quantitative way to analyze the intradomain cooperativity could be achieved by comparing the lower limit of intradomain cooperative energy (ΔGC). We first tried using the 2- or 3-site Adair function to fit the whole biphasic Tb3+ binding curve (Fig. 4a) and Ca2+ binding curve (Fig. 4b). Surprisingly, all of our attempts at fitting either yielded a 1:1 binding mode (which is clearly not the case based on visual inspection of the data) or were unsuccessful. However, by assuming that free Ca2+ concentration is close to total Ca2+ concentration, which can be justified because of the low affinity of the binding sites for Ca2+ and the use of protein concentrations 10–1000-fold lower than those of total and free Ca2+, the second transition of both Tb3+ and ANS curves, as well as the cooperative curve obtained from NMR studies (Fig. 5c), can be fitted with a two-site model-independent Adair function. We then analyzed all the titration data using the Adair function and calculated the changes in the total metal-binding free energies (ΔG2) and the lower limit of cooperative binding energy (ΔGc) (Table 3). For Ca2+ binding to subdomain 1 (from ANS fluorescence or NMR studies), the changes in total binding free energy ΔG2 was found to be 10.9–11.2 kJ/mol. The intradomain cooperativity estimated by ΔGc was between −3.8 and −4.4 kJ/mol, which is very close to the value obtained from Tb3+-binding data (−3.9 kJ/mol). After mutating the predicted metal-binding sites 1 or 2 in subdomain 1, the changes in total binding free energy ΔG2 were decreased by 1.2 or 2.1 kJ/mol, respectively. Compared to subdomain 1, subdomain 2, a truncated version of subdomain 1 that lacks the hinge region and part of predicted site 1, had a less favorable ΔG2 with a ΔΔG2 of + 1.9 kJ/mol. For subdomain 3, mutagenesis within site 4 or 5 also resulted in a less favorable ΔG2, with ΔΔG2 of + 0.7 and + 1.0 kJ/mol, respectively. All these results are consistent with the changes in macroscopic dissociation constants obtained by using the nonlinear Hill equation (Kd2, Table 2). More importantly, the apparent cooperativity reflected by ΔGc was altered after mutating key metal-binding residues within the predicted sites. In subdomain 1, the intradomain cooperativity was changed unfavorably by + 1.5 kJ/mol in mut 1 and + 0.9 kJ/mol in mut 2. Compared to subdomain 1, subdomain 2 also showed lower intradomain cooperativity (ΔΔGc = + 1.0 kJ/mol). A similar scenario was observed in subdomain 3. A drop in the intradomain cooperativity by + 0.7 or + 1.0 kJ/mol, respectively, was observed in mut 4 or mut 5 of subdomain 3.

Table 3.

The free energies of metal-binding to subdomains of CaSR.

Sample Metal Gibbs free energies (kJ/mol)
ΔG1a ΔG2a ΔGcb ΔΔG2a ΔΔGcb
subdomain 1 Tb3+ −12.0 ± 0.1 −24.5 ± 0.1 −3.9 ± 0.2 na na
d Ca2+ −5.4 ± 0.1 −11.2± 0.2 −3.8 ± 0.3 na na
e Ca2+ −5.0 ± 0.2 −10.9 ± 0.1 −4.4 ± 0.3 na na
 subdomain 1 mut 1 Tb3+ −12.1 ± 0.1 −23.3 ± 0.1 −2.4 ± 0.1 + 1.2 ± 0.2 + 1.5 ± 0.3
 subdomain 1 mut 2 Tb3+ −11.4± 0.1 −22.4 ± 0.1 −3.0 ± 0.2 + 2.1 ± 0.2 + 0.9 ± 0.3
 subdomain 2 Tb3+ −11.6 ± 0.1 −22.6 ± 0.1 −2.9 ± 0.1 + 1.9 ± 0.2 + 1.0 ± 0.3

subdomain 3 Tb3+ −10.1 ± 0.1 −20.1 ± 0.1 −3.3 ± 0.2 na na
 subdomain 3 mut 4 Tb3+ −10.2 ± 0.1 −19.4 ± 0.1 −2.4 ± 0.1 + 0.7 ± 0.2 + 0.9 ± 0.3
 subdomain 3 mut 5 Tb3+ −9.9 ± 0.1 −19.1 ± 0.1 −2.7 ± 0.2 + 1.0 ± 0.2 + 0.6 ± 0.3

Mutations of putative Ca2+-binding ligand residues alters the intracellular Ca2+ response of the CaSR

To investigate the role of the proposed Ca2+-binding sites in the biological functions of the CaSR, we created several mutations in the full length intact CaSR (E297I in site 1 located at the crevice, D215I in site 2, and E228/229I in site 3). These mutants were overexpressed in HEK293 cells, which contain no endogenous CaSR (3). The effects of the mutations in the CaSR on intracellular Ca2+ signaling are summarized in Table 4 and Fig. 7. Compared to the wild type CaSR, the mutant receptor containing the mutation E297I in site 1 exhibited significantly impaired sensitivity to [Ca2+]o with an increase in EC50 from 2.8 ± 0.3 mM to 10.0 ± 0.2 mM and a decrease in the Hill coefficient from 2.9 ± 0.2 to 1.5 ± 0.2. In addition, the EC50 for the D215I mutant in site 2 increased to 6.3 ± 0.2 mM, while the maximal response in the E228I/E229I mutant in site 3 decreased to 64 ± 3 %.

Table 4.

Summary of the intracellular Ca2+ response in CaSR and mutants

EC50 (mM) Maximal response (%) Hill Coefficient
WT 2.8 ± 0.3 100 2.9 ± 0.2
Site1 E297I 10.0 ± 0.2* 89 ± 5 1.5 ± 0.2*
Site2 D215I 6.3 ± 0.2* 90 ± 2 2.5 ± 0.3
Site3 E228/229I 3.2 ± 0.3 64 ± 3* 2.6 ± 0.3

Figure 7.

Figure 7

The intracellular Ca2+ response of HEK293 cells transiently overexpressing the wild type CaSR and its various mutants using Fura-2 AM during stepwise increases of extracellular [Ca2+] from 0.5 to 20.5 mM.

DISCUSSION

Correlation of predicted metal-binding sites with disease-associated mutations

Responding to a narrow range of [Ca2+]o, the CaSR is able to trigger multiple intracellular signalling pathways, including cooperative changes in [Ca2+]i. The CaSR has been linked to a number of human diseases, such as FHH, NSHPT, or ADH (7, 10). Among these, FHH and NSHPT are characterized by reduced sensitivity of the CaSR to [Ca2+]o, whereas the CaSRs of patients with ADH are oversensitive to changes in [Ca2+]o.

We have predicted five potential Ca2+-binding sites within the CaSR’s ECD based on homology modeling and analysis of its geometric properties and charge distributions. Fig. 1 shows the model structure of the putative Ca2+-binding sites 1, 2 and 3 and surrounding disease-associated mutations. In site 1, Y218S and E297K, with mutations on the ligand residues, and L174R, R185Q and P221S, with mutations close to the ligand residues, inactivate the CaSR, while P221L activates the protein. Similarly, related to site 2, E250K is an inactivating mutation and Q245R is an activating mutation. Related to site 3, R220W/Q are inactivating mutations and E228Q is an activating mutation. Among these mutations, E297K, L174R, R185Q, Q245R, and R220W/Q might disturb the charge balance in the Ca2+-binding pocket, resulting in a reduced Ca2+-binding affinity of the CaSR and thus an impaired Ca2+ sensitivity of the CaSR with a right-shifted intracellular Ca2+ response curve. The Y218S mutation is also expected to decrease the binding affinity of the CaSR for Ca2+ due to the much shorter side chain of Ser compared to that of Tyr. The mutations on P221 have opposite effects (10), possibly due to their different effects on the α-helical structures. Leu favors the formation of α-helix, while Ser is an unfavored residue for α-helix formation. The activating mutation, E228Q, could reduce the net negative charge of site 3 and reduce the repulsion between those ligands, resulting in increased binding affinity for Ca2+. The presence of disease-associated mutations within the proposed Ca2+-binding ligands in all these predicted sites (Table 2) suggests a link between these diseases and the impaired Ca2+-binding capabilities of the respective mutant receptors.

Although no disease-associated mutations are present on the proposed ligand residues in sites 4 and 5, our previous functional data suggest that the mutations of the ligands in predicted site 5 lead to opposite effects on the [Ca2+]i change in response to [Ca2+]o (19). The double mutant E378I/E379I results in a left-shifted, whereas the double mutant E398I/E399I produces a right-shifted concentration-response curve to [Ca2+]o. The effects of other disease-associated mutations around the Ca2+ -binding sites on the Ca2+-binding properties will be a subject of further investigation in our laboratory.

Multiple cooperative metal-binding processes

Functional studies as well as our metal-binding studies demonstrate that CaSR has multiple Ca2+-binding sites (27). We have previously investigated the site-specific metal-binding properties of two continuous predicted sites (site 3 and site 5 in the present study) by grafting them individually into the host protein, CD2 (19). Site-directed mutations on engineered proteins and the full length CaSR support the idea that the predicted Ca2+-binding residues are important in Ca2+-binding capability and in regulating CaSR functions. Interestingly, these probed site-specific Ca2+-binding affinities (4–20 mM) are weaker than the EC50 (2.7–3.1 mM) of the CaSR for Ca2+ (19), possibly due to the fact that the additional structural constraints imposed on the domain structures when they are in the intact ECD have additional effects not revealed in the structures of the isolated subdomains. In addition, some of the mutations within the predicted sites exhibit opposite effects on the protein’s sensitivity to its native ligand. These observations indicate that binding of Ca2+ at different locations has diverse influences on the binding of subsequent Ca2+ ions and that the interaction of coupled metal-binding sites and cooperativity are likely to contribute to the overall capacity of the intact CaSR to respond to [Ca2+]o.

Dissecting of metal-binding sites utilizing subdomains has been successfully applied to EF-hand Ca2+-binding proteins, such as calmodulin and calbindin D28K (38, 39). We have constructed three subdomains of the CaSR and each subdomain contains 2–3 predicted Ca2+-binding sites. The purified subdomains are well-folded as suggested by the CD, fluorescence and NMR spectra. These well-folded domains allow us to visualize multiple metal-binding processes within each subdomain and metal-dependent conformational changes within the subdomains.

Tb3+ and Ca2+ titrations clearly show that at least two distinct metal-binding processes occur in subdomain 1. The fluorescence intensity and binding affinity are significantly reduced when any one of the three predicted sites is removed, indicating that the predicted Ca2+-binding sites function in concert, and each site is crucial for maintaining the observed binding process. In particular, studies using site- directed mutagenesis suggest that predicted sites 1 and 3 are mainly responsible for the first and second components of the titration curve, respectively (Fig. 4 and Table 2). The second transition is cooperative with an apparent intradomain cooperativity of −3.8 ~ −4.4 kJ/mol. Furthermore, the impaired Ca2+-binding ability coincides with abnormal [Ca2+]i responses mediated by the CaSR in HEK cells. In particular, the mutation E297I in the full length CaSR results in a striking right shift of the Ca2+ concentration-response curve. Concomitantly, the Hill coefficient was reduced from 2.9 ± 0.2 to 1.5 ± 0.2, which is in agreement with the abolition of the first binding process in subdomain 1 (Table 2 and Fig. 4). Thus, it seems that site 1 has a higher binding affinity than site 2 and plays the major role in sensing low levels of plasma [Ca2+]; in addition, the binding of Ca2+ to site 1, situated in the hinge region of the CaSR, lowers the energy barrier and enables further cooperative binding of Ca2+ ions to the other sites. This view is further corroborated by the fact that mutating key metal-binding residues in site 1 leads to a significant decrease in the changes of free energy for metal-binding to subdomain 1 (ΔΔG2 = +1.2 kJ/mol) as well as a drop in the intradomain cooperativity by + 1.5 kJ/mol. Our site-directed mutagenesis studies also suggest that predicted Ca2+-binding site 3 in subdomain 1 plays unique roles in the Ca2+-binding and sensing events. The charged-ligand mutations in this site abolished the second component of metal-binding in subdomain 1 (Fig. 4). Correspondingly, the maximal response of the mutant containing the E228I/E229I mutations in the full length CaSR was significantly decreased, suggesting that site 3 is indeed crucial for transducing [Ca2+]o to intracellular Ca2+ signals.

In subdomain 3, we also observed a cooperative binding curve, suggesting the existence of more than one binding site in the protein. Fitting the binding curve with a two-site Adair function resolves a lower limit of change in intradomain cooperativity, with ΔGc of −3.3 kJ/mol. Similar to the scenario observed in subdomain 1, mutations on either of the two predicted sites (sites 4 and 5) results in significant decrease in ΔG2 by + 0.7 to + 1.0 kJ/mol and lowers the intradomain cooperativity by + 0.6 to + 0.9 kJ/mol. The metal selectivity screening experiments indicate that the CaSR has a wide spectrum of metal agonists, including at least Mg2+, Ca2+ and its trivalent analogs Tb3+ and La3+, which is consistent with previous reports (36). This observed cooperativity could be the result of direct site-to-site interactions or Ca2+-induced conformational change. If Ca2+ effectively cross-linked and neutralized negative charges in two different parts of the molecule, which then caused the lobes to close, then loss of one of those negative charges could reduce the repulsion between the negative charges that was present in the absence of Ca2+ and favor activation of the receptor at lower extracellular Ca2+.

Ca2+-induced conformational changes

Ca2+-induced conformational changes were observed in both fluorescence and NMR studies. The ANS binding assay further suggests that Ca2+ binding results in more exposure of hydrophobic regions. However, the removal of any one of the three predicted sites eliminates such significant Ca2+-induced conformational changes. Suggested by the glutamate-binding that occurs in mGluR1, the hinge that connects the two lobes directly responds to the stimuli-inducing receptor activation in the GPCR family C proteins. The predicted Ca2+-binding site in the crevice is likely to play an important role in modulating the function of the CaSR by Ca2+-induced conformational change (19).

Based on all these results, we postulate a working model for the CaSR with emphasis on the roles of the predicted Ca2+-binding sites (Fig. 8). Under normal physiological conditions with a [Ca2+]o of 1.1–1.3 mM, the active and inactive forms of the CaSR are in dynamic equilibrium with each other. The “high-affinity” site (site 1 with a Kd ~0.5–1 mM) is responsible for the sensing and maintenance of this balance. If [Ca2+]o is lower than the physiological level, the balance would shift to the inactive form of the CaSR and Ca2+ might dissociate from site 1, which would change the conformation of the CaSR. Such conformational changes are further relayed to the cytoplasm, leading to a signaling cascade favoring the secretion of PTH, which, in turn, elevates extracellular Ca2+. On the other hand, under abnormally high [Ca2+]o conditions, the Ca2+-binding sites are loaded with Ca2+ ions, and the CaSR exists in a conformation that is persistently activated. Ca2+-binding to weak sites (most probably sites 4 and 5 with affinities at low mM range) results in further conformational changes that activate signaling cascades in favor of inhibition of PTH secretion as well as stimulation of renal Ca2+ excretion and secretion of calcitonin (CT), a hormone known to reduce extracellular [Ca2+]. In this way, deviations from homeostatic balance can be self-corrected by modulating the activities of different signaling pathways in cell types involved in maintaining Ca2+ homeostasis (e.g., parathyroid, kidney and C-cells).

Fig. 8. A “two-state” working model of CaSR.

Fig. 8

The active and inactive forms are in equilibrium and the state of the receptor’s activity varies in response to the association or dissociation of Ca2+ ions in the predicted Ca2+-binding sites. The high-affinity site 1 (with a Kd of ~ 0.5–1 mM) is capable of sensing the normal range of [Ca2+]o. Both forms are in dynamic equilibrium in the normal physiological range of [Ca2+]o. Under low [Ca2+]o conditions, the Ca2+-binding sites are largely devoid of ions, and the CaSR ECD exists as an inactive open form that favors PTH secretion. PTH is responsible for elevating [Ca2+]o. Under high extracellular Ca2+ conditions, the binding of Ca2+ to all sites leads to conformational changes that favor activation of the receptor, which produces several homeostatic responses designed to normalize [Ca2+]o. These include inhibition of PTH secretion, stimulation of calcitonin (CT) secretion, a hormone that reduces [Ca2+]o, and enhancement of renal Ca2+ excretion. Thus, deviation from the state of homeostasis can be restored by the sensing of [Ca2+]o by these putative Ca2+-binding sites and the resultant reversible conformational changes.. The filled circles indicate the loading of the sites with Ca2+, while the empty circles indicate the absence of Ca2+.

This model is consistent with the disease-associated mutations. In loss-of-function diseases, such as FHH/NSHPT, which are characterized by hypercalcemia, the Ca2+-binding ability of the CaSR is decreased, which shifts the balance to the inactive form. This leads to an increase in PTH secretion resulting in hypercalcemia. On the other hand, in the gain-of-function disease, ADH, some of the activating mutations increase the Ca2+-binding site(s)’ affinities, thereby inhibiting PTH secretion and renal tubular Ca2+ reabsorption and stimulating calcitonin secretion, which leads to hypocalcemia and hypercalciuria.

Overall, our findings provide further insights into the molecular mechanisms of the family of class III G protein-coupled receptors that are regulated by extracellular Ca2+ signaling. Our study describes a methodology for dissecting factors in Ca2+-binding, thereby contributing to our understanding of the general mechanism of Ca2+-modulated conformational change of the CaSR, which can be correlated with its biological function. In addition, the present study explores an approach to visualizing and probing Ca2+-binding sites at simplified and more readily approachable levels, overcoming the obstacles encountered in expression and purification of highly-hydrophobic membrane proteins. Indeed, this strategy for prediction and evaluation of Ca2+-binding sites in the CaSR will likely also be useful for probing the roles of Ca2+ in many other proteins for which structural information is lacking.

Supplementary Material

1_si_001. SUPPORTING INFORMATION.

Table S1 summarizes the Stern-Volmer quenching constants of subdomains. Fig. S1 illustrates the modeled structures of subomain 2 and subdomain 3 and the SDS-PAGE of purified subdomains. Fig. S2a shows the near UV CD spectra of subdomain 1 in the absence or in the presence of Ca2+. Fig. S2b is the overall solvent accessibility of the tryptophan residues within each subdomain using fluorescence quenching with acrylamide. Fig. S3 shows the methyl group region of the 1D 1H NMR spectrum of subdomain 1. This material is available free of charge via the internet at http://pubs.acs.org.

Acknowledgments

We thank Dr. Hai Deng, Xue Wang and Dr. G. T. Chen for the prediction of Ca2+ binding sites in CaSR using GG program. We thank Dan Adams for help in preparation of this manuscript and Mei Bai, Aldebaran Hofer, Hing-Cheung Wong and other members from Yang group for their helpful suggestions.

BRIEFS

CD2

cluster of differentiation 2

EGTA

ethylene glycol tetraacetic acid

PBS

phosphate buffered saline

NMR

nuclear magnetic resonance

PTH

parathyroid hormone

Footnotes

This work was supported, in part, by National Institutes of Health Grants GM62999-1 and GM081749-01, National Science Foundation Grant MCB-0092486, American Heart Association Grant 0655168B (to J. J. Y.), and a Predoctoral Fellowship from the Brain and Behavior Program at Georgia State University (to Y. H.).

References

  • 1.Gao ZG, Jacobson KA. Keynote review: allosterism in membrane receptors. Drug Discov Today. 2006;11:191–202. doi: 10.1016/S1359-6446(05)03689-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580. doi: 10.1038/366575a0. [DOI] [PubMed] [Google Scholar]
  • 3.Bai M, Trivedi S, Brown EM. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J Biol Chem. 1998;273:23605–23610. doi: 10.1074/jbc.273.36.23605. [DOI] [PubMed] [Google Scholar]
  • 4.Brown EM, Chattopadhyay N, Vassilev PM, Hebert SC. The calcium-sensing receptor (CaR) permits Ca2+ to function as a versatile extracellular first messenger. Recent Prog Horm Res. 1998;53:257–280. [PubMed] [Google Scholar]
  • 5.Shapiro L, Colman DR. Structural biology of cadherins in the nervous system. Curr Opin Neurobiol. 1998;8:593–599. doi: 10.1016/s0959-4388(98)80086-x. [DOI] [PubMed] [Google Scholar]
  • 6.Bai M. Structure-function relationship of the extracellular calcium-sensing receptor. Cell Calcium. 2004;35:197–207. doi: 10.1016/j.ceca.2003.10.018. [DOI] [PubMed] [Google Scholar]
  • 7.Hu J, Mora S, Colussi G, Proverbio MC, Jones KA, Bolzoni L, De Ferrari ME, Civati G, Spiegel AM. Autosomal dominant hypocalcemia caused by a novel mutation in the loop 2 region of the human calcium receptor extracellular domain. J Bone Miner Res. 2002;17:1461–1469. doi: 10.1359/jbmr.2002.17.8.1461. [DOI] [PubMed] [Google Scholar]
  • 8.Hu J, Reyes-Cruz G, Chen W, Jacobson KA, Spiegel AM. Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. J Biol Chem. 2002;277:46622–46631. doi: 10.1074/jbc.M207100200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pearce SH. Clinical disorders of extracellular calcium-sensing and the molecular biology of the calcium-sensing receptor. Ann Med. 2002;34:201–206. [PubMed] [Google Scholar]
  • 10.Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium. 2004;35:275–282. doi: 10.1016/j.ceca.2003.10.010. [DOI] [PubMed] [Google Scholar]
  • 11.Bai M, Trivedi S, Kifor O, Quinn SJ, Brown EM. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc Natl Acad Sci U S A. 1999;96:2834–2839. doi: 10.1073/pnas.96.6.2834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mun HC, Franks AH, Culverston E, Krapcho K, Nemeth EF, Conigrave AD. The extracellular Ca2+-sensing receptor’s venus fly trap domain is required for L-amino acid sensing. J Biol Chem. 2004;279:51739–51744. doi: 10.1074/jbc.M406164/200. [DOI] [PubMed] [Google Scholar]
  • 13.Babu YS, Bugg CE, Cook WJ. Structure of calmodulin refined at 2.2 A resolution. J Mol Biol. 1988;204:191–204. doi: 10.1016/0022-2836(88)90608-0. [DOI] [PubMed] [Google Scholar]
  • 14.Kawasaki H, Kretsinger RH. Calcium-binding proteins 1: EF-hands. Protein Profile. 1995;2:297–490. [PubMed] [Google Scholar]
  • 15.Pertz O, Bozic D, Koch AW, Fauser C, Brancaccio A, Engel J. A new crystal structure, Ca2+ dependence and mutational analysis reveal molecular details of E-cadherin homoassociation. Embo J. 1999;18:1738–1747. doi: 10.1093/emboj/18.7.1738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature. 2000;407:971–977. doi: 10.1038/35039564. [DOI] [PubMed] [Google Scholar]
  • 17.Deng H, Chen G, Yang W, Yang JJ. Predicting calcium-binding sites in proteins-A graph theory and geometry approach. Proteins. 2006;64:34–42. doi: 10.1002/prot.20973. [DOI] [PubMed] [Google Scholar]
  • 18.Yang W, Wilkins AL, Ye Y, Liu ZR, Li SY, Urbauer JL, Hellinga HW, Kearney A, van der Merwe PA, Yang JJ. Design of a calcium-binding protein with desired structure in a cell adhesion molecule. J Am Chem Soc. 2005;127:2085–2093. doi: 10.1021/ja0431307. [DOI] [PubMed] [Google Scholar]
  • 19.Huang Y, Zhou Y, Yang W, Butters R, Lee HW, Li S, Castiblanco A, Brown EM, Yang JJ. Identification and dissection of Ca(2+)-binding sites in the extracellular domain of Ca(2+)-sensing receptor. J Biol Chem. 2007;282:19000–19010. doi: 10.1074/jbc.M701096200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Higgins DG. CLUSTAL V: multiple alignment of DNA and protein sequences. Methods Mol Biol. 1994;25:307–318. doi: 10.1385/0-89603-276-0:307. [DOI] [PubMed] [Google Scholar]
  • 21.Kopp J, Schwede T. The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 2004;32:D230–234. doi: 10.1093/nar/gkh008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003;31:3381–3385. doi: 10.1093/nar/gkg520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000;29:291–325. doi: 10.1146/annurev.biophys.29.1.291. [DOI] [PubMed] [Google Scholar]
  • 24.Tsuchiya D, Kunishima N, Kamiya N, Jingami H, Morikawa K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+ Proc Natl Acad Sci U S A. 2002;99:2660–2665. doi: 10.1073/pnas.052708599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Honig B, Nicholls A. Classical electrostatics in biology and chemistry. Science. 1995;268:1144–1149. doi: 10.1126/science.7761829. [DOI] [PubMed] [Google Scholar]
  • 26.Nicholls A, Honig B. J Comput Chem. 1991;12:435–445. [Google Scholar]
  • 27.Bai M, Quinn S, Trivedi S, Kifor O, Pearce SH, Pollak MR, Krapcho K, Hebert SC, Brown EM. Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J Biol Chem. 1996;271:19537–19545. doi: 10.1074/jbc.271.32.19537. [DOI] [PubMed] [Google Scholar]
  • 28.Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem. 1989;182:319–326. doi: 10.1016/0003-2697(89)90602-7. [DOI] [PubMed] [Google Scholar]
  • 29.VanScyoc WS, Sorensen BR, Rusinova E, Laws WR, Ross JB, Shea MA. Calcium binding to calmodulin mutants monitored by domain-specific intrinsic phenylalanine and tyrosine fluorescence. Biophys J. 2002;83:2767–2780. doi: 10.1016/S0006-3495(02)75286-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pedigo S, Shea MA. Quantitative endoproteinase GluC footprinting of cooperative Ca2+ binding to calmodulin: proteolytic susceptibility of E31 and E87 indicates interdomain interactions. Biochemistry. 1995;34:1179–1196. doi: 10.1021/bi00004a011. [DOI] [PubMed] [Google Scholar]
  • 31.Rost B, Yachdav G, Liu J. The PredictProtein server. Nucleic Acids Res. 2004;32:W321–326. doi: 10.1093/nar/gkh377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16:404–405. doi: 10.1093/bioinformatics/16.4.404. [DOI] [PubMed] [Google Scholar]
  • 33.Hu J, Spiegel AM. Naturally occurring mutations of the extracellular Ca2+-sensing receptor: implications for its structure and function. Trends Endocrinol Metab. 2003;14:282–288. doi: 10.1016/s1043-2760(03)00104-8. [DOI] [PubMed] [Google Scholar]
  • 34.Fan GF, Ray K, Zhao XM, Goldsmith PK, Spiegel AM. Mutational analysis of the cysteines in the extracellular domain of the human Ca2+ receptor: effects on cell surface expression, dimerization and signal transduction. FEBS Lett. 1998;436:353–356. doi: 10.1016/s0014-5793(98)01165-x. [DOI] [PubMed] [Google Scholar]
  • 35.Silve C, Petrel C, Leroy C, Bruel H, Mallet E, Rognan D, Ruat M. Delineating a Ca2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor. J Biol Chem. 2005;280:37917–37923. doi: 10.1074/jbc.M506263200. [DOI] [PubMed] [Google Scholar]
  • 36.Handlogten ME, Shiraishi N, Awata H, Huang C, Miller RT. Extracellular Ca(2+)-sensing receptor is a promiscuous divalent cation sensor that responds to lead. Am J Physiol Renal Physiol. 2000;279:F1083–1091. doi: 10.1152/ajprenal.2000.279.6.F1083. [DOI] [PubMed] [Google Scholar]
  • 37.Forsen S, Linse S. Cooperativity: over the Hill. Trends Biochem Sci. 1995;20:495–497. doi: 10.1016/s0968-0004(00)89115-x. [DOI] [PubMed] [Google Scholar]
  • 38.Ye Y, Lee HW, Yang W, Shealy S, Yang JJ. Probing site-specific calmodulin calcium and lanthanide affinity by grafting. J Am Chem Soc. 2005;127:3743–3750. doi: 10.1021/ja042786x. [DOI] [PubMed] [Google Scholar]
  • 39.Berggard T, Miron S, Onnerfjord P, Thulin E, Akerfeldt KS, Enghild JJ, Akke M, Linse S. Calbindin D28k exhibits properties characteristic of a Ca2+ sensor. J Biol Chem. 2002;277:16662–16672. doi: 10.1074/jbc.M200415200. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001. SUPPORTING INFORMATION.

Table S1 summarizes the Stern-Volmer quenching constants of subdomains. Fig. S1 illustrates the modeled structures of subomain 2 and subdomain 3 and the SDS-PAGE of purified subdomains. Fig. S2a shows the near UV CD spectra of subdomain 1 in the absence or in the presence of Ca2+. Fig. S2b is the overall solvent accessibility of the tryptophan residues within each subdomain using fluorescence quenching with acrylamide. Fig. S3 shows the methyl group region of the 1D 1H NMR spectrum of subdomain 1. This material is available free of charge via the internet at http://pubs.acs.org.